Montag A & Associates Inc. cut its holdings in Eli Lilly and Co (NYSE:LLY) by 3.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,517 shares of the company’s stock after selling 1,649 shares during the period. Montag A & Associates Inc.’s holdings in Eli Lilly and were worth $3,422,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Gradient Investments LLC purchased a new stake in Eli Lilly and in the 4th quarter worth approximately $103,000. Acrospire Investment Management LLC lifted its stake in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and in the 2nd quarter worth approximately $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and in the 2nd quarter worth approximately $129,000. Finally, Front Row Advisors LLC purchased a new stake in Eli Lilly and in the 4th quarter worth approximately $137,000. 76.20% of the stock is owned by institutional investors.
Several research firms have issued reports on LLY. Leerink Swann increased their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, October 24th. Goldman Sachs Group cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and increased their target price for the stock from $86.98 to $95.00 in a research note on Tuesday, January 16th. Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Finally, Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $92.02.
In related news, insider Donald A. Zakrowski sold 900 shares of Eli Lilly and stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the transaction, the insider now owns 4,130 shares in the company, valued at approximately $334,901.70. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 259,610 shares of company stock worth $22,727,406. 0.20% of the stock is owned by corporate insiders.
Shares of Eli Lilly and Co (LLY) opened at $78.02 on Friday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The firm has a market cap of $84,817.35, a price-to-earnings ratio of -390.08, a PEG ratio of 1.44 and a beta of 0.23. Eli Lilly and Co has a 52-week low of $73.69 and a 52-week high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $0.95 EPS. sell-side analysts expect that Eli Lilly and Co will post 4.87 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is presently -1,124.94%.
ILLEGAL ACTIVITY WARNING: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/16/montag-a-associates-inc-has-3-42-million-position-in-eli-lilly-and-co-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.